These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. An update on heparins at the beginning of the new millennium. Fareed J; Hoppensteadt DA; Bick RL Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802 [TBL] [Abstract][Full Text] [Related]
8. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. Fareed J; Hoppensteadt D; Schultz C; Ma Q; Kujawski MF; Neville B; Messmore H Curr Pharm Des; 2004; 10(9):983-99. PubMed ID: 15078128 [TBL] [Abstract][Full Text] [Related]
9. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680 [TBL] [Abstract][Full Text] [Related]
10. Are the available low-molecular-weight heparin preparations the same? Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734 [TBL] [Abstract][Full Text] [Related]
11. Enoxaparin: the low-molecular-weight heparin for prevention of postoperative thromboembolic complications. Carter CA; Skoutakis VA; Spiro TE; West ME; Tooms RE; Joe RH; Knutson TJ Ann Pharmacother; 1993 Oct; 27(10):1223-30. PubMed ID: 8251693 [TBL] [Abstract][Full Text] [Related]
12. Differentiation of the low-molecular-weight heparins. Racine E Pharmacotherapy; 2001 Jun; 21(6 Pt 2):62S-70S; discussion 71S-72S. PubMed ID: 11401195 [TBL] [Abstract][Full Text] [Related]
13. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Fareed J; Walenga JM; Hoppensteadt D; Huan X; Nonn R Ann N Y Acad Sci; 1989; 556():333-53. PubMed ID: 2544128 [TBL] [Abstract][Full Text] [Related]
14. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Hoppensteadt DA; Jeske W; Fareed J; Bermes EW Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S57-64. PubMed ID: 7647223 [TBL] [Abstract][Full Text] [Related]
16. Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction. Monrad ES Am J Cardiol; 2000 Apr; 85(8A):2C-9C. PubMed ID: 10793174 [TBL] [Abstract][Full Text] [Related]
17. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin. Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302 [TBL] [Abstract][Full Text] [Related]
18. Direct comparison of enoxaparin and nadroparin in a rabbit model of arterial thrombosis prevention. Vlasin M; Dvorak M; Dvorakova M; Rauser P; Lexmaulova L; Gregor Z Thromb Res; 2010 Jul; 126(1):56-60. PubMed ID: 20382412 [TBL] [Abstract][Full Text] [Related]
19. Management of thrombotic and cardiovascular disorders in the new millenium. Fareed J; Hoppensteadt DA; Bick RL Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377 [TBL] [Abstract][Full Text] [Related]
20. Are all low molecular weight heparins equivalent in the management of venous thromboembolism? Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]